Phase Separation Modulation Therapy

Target: FUS Composite Score: 0.455 Price: $0.52▲6.0% Citation Quality: Pending neurodegeneration Status: active
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
1
Opposing
Quality Report Card click to collapse
C
Composite: 0.455
Top 73% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.50 Top 76%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C+ Feasibility 12% 0.50 Top 65%
F Impact 12% 0.00 Top 50%
C+ Druggability 10% 0.50 Top 57%
C+ Safety Profile 8% 0.50 Top 57%
C+ Competition 6% 0.50 Top 77%
C+ Data Availability 5% 0.50 Top 71%
C+ Reproducibility 5% 0.50 Top 63%
Evidence
5 supporting | 1 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 0.95
Convergence
0.00 F 7 related hypothesis share this target

From Analysis:

How do host cell factors influence the conformation and propagation properties of transmitted pathological seeds?

The abstract acknowledges that host cells influence seed properties, but the specific cellular factors and mechanisms involved are not well understood. This knowledge gap limits our ability to predict disease progression and develop cell-targeted therapies. Gap type: open_question Source paper: Protein transmission in neurodegenerative disease. (2020, Nat Rev Neurol, PMID:32203399)

→ View full analysis & debate transcript

Description

Disruption of biomolecular condensates that facilitate seed propagation while preserving normal phase separation functions

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.50 (8%) 0.455 composite
6 citations 6 with PMID 5 medium Validation: 0% 5 supporting / 1 opposing
For (5)
5
No opposing evidence
(1) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
1
3
MECH 2CLIN 1GENE 3EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
FUS-dependent liquid-liquid phase separation is im…SupportingGENEJ Cell Biol MEDIUM2021-PMID:33704371-
Phase Separation of FUS Is Suppressed by Its Nucle…SupportingGENECell MEDIUM2018-PMID:29677514-
Antisense oligonucleotide silencing of FUS express…SupportingCLINNat Med MEDIUM2022-PMID:35075293-
FUS gene mutation in amyotrophic lateral sclerosis…SupportingGENEAmyotroph Later… MEDIUM2024-PMID:37926865-
Functional Ultrasound Neuroimaging.SupportingMECHAnnu Rev Neuros… MEDIUM2022-PMID:35803584-
No claimOpposingMECH- MODERATE2023-PMID:37720552-
Legacy Card View — expandable citation cards

Supporting Evidence 5

FUS-dependent liquid-liquid phase separation is important for DNA repair initiation. MEDIUM
J Cell Biol · 2021 · PMID:33704371
Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. MEDIUM
Cell · 2018 · PMID:29677514
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral scleros… MEDIUM
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.
Nat Med · 2022 · PMID:35075293
FUS gene mutation in amyotrophic lateral sclerosis: a new case report and systematic review. MEDIUM
Amyotroph Lateral Scler Frontotemporal Degener · 2024 · PMID:37926865
Functional Ultrasound Neuroimaging. MEDIUM
Annu Rev Neurosci · 2022 · PMID:35803584

Opposing Evidence 1

No claim MODERATE
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-10 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on the knowledge gap regarding host cell factors influencing pathological seed conformation and propagation, here are my novel therapeutic hypotheses:

Hypothesis 1: Chaperone Network Reprogramming Therapy

Description: Host cell chaperone networks (HSP70, HSP90, co-chaperones) can be therapeutically reprogrammed to selectively recognize and refold incoming pathological protein seeds before they template endogenous proteins. By enhancing specific chaperone-co-chaperone complexes while inhibiting others, we can create a cellular environment that converts pathological conformations t

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

I'll provide a rigorous critique of each hypothesis, identifying specific weaknesses, alternative explanations, and key experiments needed for falsification.

Hypothesis 1: Chaperone Network Reprogramming Therapy

Confidence: 0.7 → Revised: 0.3

Critical Weaknesses:

  • Oversimplified chaperone selectivity: The hypothesis assumes chaperones can be "reprogrammed" to selectively target pathological conformations without affecting normal protein folding. However, chaperones recognize hydrophobic patches and misfolded structures generally - they lack inherent specificity for pathologi
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    PRACTICAL FEASIBILITY ASSESSMENT

    Based on my analysis of these hypotheses, I'll assess their druggability, existing therapeutic landscape, and development feasibility:

    HYPOTHESIS 1: Chaperone Network Reprogramming

    DRUGGABILITY: MODERATE

    Existing Chemical Matter:

    • HSP90 inhibitors: Geldanamycin analogs (17-AAG, 17-DMAG) - multiple failed trials
    • HSP70 allosteric modulators: YM-08, JG-98 (tool compounds)
    • Co-chaperone modulators: Limited, mostly academic tools
    Competitive Landscape:
    • Neurimmune/Roche abandoned HSP70 programs after Phase I failures
    • Synta Pharmaceutica

    Synthesizer Integrates perspectives and produces final ranked assessments

    Based on the comprehensive debate analysis, here is my synthesis of the therapeutic hypotheses with scored rankings:

    Price History

    0.460.490.52 0.54 0.43 2026-04-212026-04-252026-04-28 Market PriceScoreevidencedebate 8 events
    7d Trend
    Stable
    7d Momentum
    ▲ 7.4%
    Volatility
    High
    0.0535
    Events (7d)
    7

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (6)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📅 Citation Freshness Audit

    Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

    No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    5

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.505

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    📋 Reviews View all →

    Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

    💬 Discussion

    No DepMap CRISPR Chronos data found for FUS.

    Run python3 scripts/backfill_hypothesis_depmap.py to populate.

    No curated ClinVar variants loaded for this hypothesis.

    Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

    🔍 Search ClinVar for FUS →
    Loading history…

    ⚖️ Governance History

    No governance decisions recorded for this hypothesis.

    Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

    Browse all governance decisions →

    KG Entities (33)

    ATF5ATP6V1AFUSHMGCRHSPA1AKIF5ALTN1UPRmtbenign or degradable formsbiomolecular condensateschaperone-co-chaperone complexesconformational selectivitydegradative compartmentslysosomal acidificationlysosomal pHmembrane lipid compositionmitochondrial proteostasismotor protein adaptorsneurodegenerationpathological conformations

    Related Hypotheses

    ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis
    Score: 0.720 | neurodegeneration
    Arginine Methylation Loss on FUS RGG Domains Drives Irreversible Phase Transition to Amyloid in ALS
    Score: 0.676 | ALS
    RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation as proximal driver in Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates
    Score: 0.626 | neurodegeneration
    mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling as proximal driver in Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular Denervation
    Score: 0.626 | neurodegeneration
    FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resistance
    Score: 0.613 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (25 edges)

    associated with (2)

    LTN1ribosome-associated quality controlATP6V1Aneurodegeneration

    converts (1)

    pathological conformationsbenign or degradable forms

    distinguishes (2)

    conformational selectivitypathological protein statesconformational selectivityphysiological protein states

    drives (1)

    FUSphase separation

    eliminates (1)

    ribosome-associated quality controlseed-templated nascent proteins

    enables (1)

    lysosomal acidificationprotein degradation

    encodes (1)

    KIF5Amotor protein adaptors

    encodes subunit of (2)

    ATP6V1Av-ATPaseATP6V1Alysosomal acidification

    enhances (1)

    HSPA1Achaperone-co-chaperone complexes

    facilitates (2)

    HSPA1Aprotein foldingbiomolecular condensatesseed propagation

    forms (1)

    phase separationbiomolecular condensates

    misdirects (1)

    motor protein adaptorspathological seeds

    modulates (3)

    v-ATPaselysosomal pHHMGCRmembrane lipid compositionmembrane lipid compositionseed uptake

    prevents (1)

    protein foldingprotein aggregation

    protects against (1)

    protein degradationneurodegeneration

    regulates (1)

    UPRmtmitochondrial proteostasis

    resists (1)

    mitochondrial proteostasisseed-induced protein misfolding

    targets (1)

    pathological seedsdegradative compartments

    transcriptional activator of (1)

    ATF5UPRmt

    Mechanism Pathway for FUS

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        ATP6V1A["ATP6V1A"] -->|encodes subunit of| v_ATPase["v-ATPase"]
        ATP6V1A_1["ATP6V1A"] -->|encodes subunit of| lysosomal_acidification["lysosomal acidification"]
        v_ATPase_2["v-ATPase"] -->|modulates| lysosomal_pH["lysosomal pH"]
        lysosomal_acidification_3["lysosomal acidification"] -->|enables| protein_degradation["protein degradation"]
        protein_degradation_4["protein degradation"] -->|protects against| neurodegeneration["neurodegeneration"]
        ATF5["ATF5"] -->|transcriptional ac| UPRmt["UPRmt"]
        UPRmt_5["UPRmt"] -->|regulates| mitochondrial_proteostasi["mitochondrial proteostasis"]
        mitochondrial_proteostasi_6["mitochondrial proteostasis"] -->|resists| seed_induced_protein_misf["seed-induced protein misfolding"]
        HSPA1A["HSPA1A"] -->|facilitates| protein_folding["protein folding"]
        HSPA1A_7["HSPA1A"] -->|enhances| chaperone_co_chaperone_co["chaperone-co-chaperone complexes"]
        protein_folding_8["protein folding"] -->|prevents| protein_aggregation["protein aggregation"]
        pathological_conformation["pathological conformations"] -->|converts| benign_or_degradable_form["benign or degradable forms"]
        style ATP6V1A fill:#ce93d8,stroke:#333,color:#000
        style v_ATPase fill:#4fc3f7,stroke:#333,color:#000
        style ATP6V1A_1 fill:#ce93d8,stroke:#333,color:#000
        style lysosomal_acidification fill:#81c784,stroke:#333,color:#000
        style v_ATPase_2 fill:#4fc3f7,stroke:#333,color:#000
        style lysosomal_pH fill:#4fc3f7,stroke:#333,color:#000
        style lysosomal_acidification_3 fill:#81c784,stroke:#333,color:#000
        style protein_degradation fill:#4fc3f7,stroke:#333,color:#000
        style protein_degradation_4 fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration fill:#ef5350,stroke:#333,color:#000
        style ATF5 fill:#ce93d8,stroke:#333,color:#000
        style UPRmt fill:#81c784,stroke:#333,color:#000
        style UPRmt_5 fill:#81c784,stroke:#333,color:#000
        style mitochondrial_proteostasi fill:#4fc3f7,stroke:#333,color:#000
        style mitochondrial_proteostasi_6 fill:#4fc3f7,stroke:#333,color:#000
        style seed_induced_protein_misf fill:#4fc3f7,stroke:#333,color:#000
        style HSPA1A fill:#ce93d8,stroke:#333,color:#000
        style protein_folding fill:#4fc3f7,stroke:#333,color:#000
        style HSPA1A_7 fill:#ce93d8,stroke:#333,color:#000
        style chaperone_co_chaperone_co fill:#4fc3f7,stroke:#333,color:#000
        style protein_folding_8 fill:#4fc3f7,stroke:#333,color:#000
        style protein_aggregation fill:#4fc3f7,stroke:#333,color:#000
        style pathological_conformation fill:#4fc3f7,stroke:#333,color:#000
        style benign_or_degradable_form fill:#4fc3f7,stroke:#333,color:#000

    3D Protein Structure

    🧬 FUS — PDB 4FDD Click to expand 3D viewer

    Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

    Source Analysis

    How do host cell factors influence the conformation and propagation properties of transmitted pathological seeds?

    neurodegeneration | 2026-04-08 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    Same Analysis (5)

    Membrane Lipid Composition Therapeutic Modulation
    Score: 0.46 · HMGCR
    Chaperone Network Reprogramming Therapy
    Score: 0.46 · HSPA1A
    Mitochondrial Proteostasis Coupling Therapy
    Score: 0.46 · ATF5
    Lysosomal pH Gradient Manipulation
    Score: 0.46 · ATP6V1A
    Ribosomal Stress Response Exploitation
    Score: 0.46 · LTN1
    → View all analysis hypotheses
    Public annotations (0)Annotate on Hypothes.is →
    No public annotations yet.